Opinion|Videos|July 16, 2024

Navigating Biosimilar Uptake in New Patients

The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.

Video content above is prompted by the following:

  • How do you direct new-start patients to a biosimilar? What about switching?
  • Payers require generic medications over brand name in most instances. Why isn’t this the case for biosimilars?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo